CAR-T cell therapy for hard-to-treat autoimmune diseases
Part of Brain & nervous system, Cancer, Eyes & vision, Immune system & allergy, Skin clinical trials.
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with one of these autoimmune diseases for at least 6 months: lupus, necrotizing myopathy, neuromyelitis optica, multiple sclerosis, myasthenia gravis, or systemic sclerosis.
- Your disease is still active or has come back after trying at least two standard treatments.
- Your major organs (like bone marrow, heart, lungs, liver, and kidneys) are working well enough.
- You have not had a positive test for hepatitis B or C, HIV, or other active viruses, and you do not have an active infection.
- You have not received any past CAR-T cell therapy or a stem cell/organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of cell therapy called CAR-T cells that target three proteins (CD19, CD22, BCMA) to treat people with autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity.
This early-stage trial tests a new type of cell therapy (CAR-T cells) designed to treat severe autoimmune diseases where the immune system attacks the body's own organs. The therapy targets specific immune cells (B cells) that may be causing the disease. It may help patients who haven't improved with standard treatments or can't tolerate them.
This trial tests a new treatment called C-CAR168 for people with certain autoimmune diseases that have not improved with standard therapies. It aims to see if this treatment can help control the disease.
This trial tests a new treatment using your own immune cells (called CAR-T cells) designed to target and attack cells that cause autoimmune diseases. It is for people with lupus, Sjögren's syndrome, inflammatory myopathy, scleroderma, Behcet's disease, ANCA-associated vasculitis, IgG4-related disease, antiphospholipid syndrome, or thrombotic thrombocytopenic purpura who have not improved with standard therapies.
This trial tests a new cell therapy called C-CAR168 for people with autoimmune diseases affecting the brain and spinal cord, such as multiple sclerosis, neuromyelitis optica, autoimmune encephalitis, or stiff person spectrum disorder. It is for patients whose condition has not improved with standard treatments.
This study tests a new cell therapy called CAR-T (using your own immune cells) for people with severe autoimmune diseases like lupus, scleroderma, or myositis that have not improved with standard treatments. The goal is to see if it can safely reduce disease activity.
Hear when a new Neuromyelitis Optica Spectrum Disorders (NMOSD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.